Investigational melatonin receptor agonists

Bibliography

• Tan D-X, Manchester LC, Hardeland R, Melatonin – a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003;34:75-8
   PubMed Web of Science ®Google Scholar
• Hardeland R, Poeggeler B. Melatonin beyond its classical functions. Open Physiol J 2008;1:1-23
   Google Scholar
• Hardeland R. Melatonin, hormone of darkness and more – occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci 2008;65:2001-18
   PubMed Web of Science ®Google Scholar
• Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. BioFactors 2009;35:183-92
   PubMed Web of Science ®Google Scholar
• Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005;9:25-39
   PubMed Web of Science ®Google Scholar
• Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem 2006;43:344-53
   PubMed Web of Science ®Google Scholar
• Arendt J, Van Someren EJ, Appleton R, Clinical update: melatonin and sleep disorders. Clin Med 2008;8:381-3
   PubMed Web of Science ®Google Scholar
• Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009;5:341-54
   PubMed Web of Science ®Google Scholar
• Torres K, Staśkiewicz GJ, Darocha T, Morphometry of the pineal gland in overweight individuals. Ann Univ Mariae Curie Sklodowska Med 2003;58:270-5
   PubMedGoogle Scholar
• Barrenetxe J, Delagrange P, Martínez JA. Physiological and metabolic functions of melatonin. J Physiol Biochem 2004;60:61-72
   PubMed Web of Science ®Google Scholar
• Müller HL, Handwerker G, Gebhardt U, Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. Cancer Causes Control 2006;17:583-9
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Popovich IG, Zabezhinski MA, Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006;1757:573-89
   PubMed Web of Science ®Google Scholar
• Cervantes M, Moralí G, Letechipía-Vallejo G. Melatonin and ischemia-reperfusion injury of the brain. J Pineal Res 2008;45:1-7
   PubMed Web of Science ®Google Scholar
• Tengattini S, Reiter RJ, Tan D-X, Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008;44:16-25
   PubMed Web of Science ®Google Scholar
• Korkmaz A, Reiter RJ, Topal T, Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009;15:43-50
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Srinivasan V, Poeggeler B, Drug insight: the use of melatonergic agonists for the treatment of insomnia – focus on ramelteon. Nat Clin Pract Neurol 2007;3:221-8
   PubMedGoogle Scholar
• Srinivasan V, Pandi-Perumal SR, Trahkt I, Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009;119:821-6
   PubMed Web of Science ®Google Scholar
• Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev 2005;9:11-24
   PubMed Web of Science ®Google Scholar
• Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev Neurother 2006;6:957-64
   PubMedGoogle Scholar
• Lewy AJ, Ahmed S, Latham Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992;9:380-92
   PubMed Web of Science ®Google Scholar
• van der Heijden KB, Smits MG, van Someren EJ, Boudewijn Gunning W. Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia. J Sleep Res 2005;14:1987-94
   Web of Science ®Google Scholar
• Hoebert M, van der Heijden KB, van Geijlswijk IM, Smits MG. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res 2005;47:1-7
   Web of Science ®Google Scholar
• Arendt J. Does melatonin improve sleep? Efficacy of melatonin. BMJ 2006;332:550
   Google Scholar
• Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Melatonin – nature's most versatile biological signal? FEBS J 2006;273:2813-38
   PubMed Web of Science ®Google Scholar
• Reppert SM, Godson C, Mahle CD, Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995;92:8734-8
   PubMed Web of Science ®Google Scholar
• Jin X, von Gall C, Pieschl RL, Targeted disruption of the mouse Mel1b melatonin receptor. Mol Cell Biol 2003;23:1054-60
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-10
   PubMed Web of Science ®Google Scholar
• Korf HW, von Gall C. Mice, melatonin and the circadian system. Mol Cell Endocrinol 2006;252:57-68
   PubMed Web of Science ®Google Scholar
• Kato K, Hirai K, Nishiyama K, Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301-10
   PubMed Web of Science ®Google Scholar
• Hardeland R, Poeggeler B, Srinivasan V, Melatonergic drugs in clinical practice. Arzneimittelforschung 2008;58:1-10
   PubMed Web of Science ®Google Scholar
• Liu C, Weaver DR, Jin X, Molecular dissection of two distinct actions of melatonin on the suprachiasmatic clock. Neuron 1997;19:91-102
   PubMed Web of Science ®Google Scholar
• von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 2002;309:151-62
   PubMed Web of Science ®Google Scholar
• Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437:1257-63
   PubMed Web of Science ®Google Scholar
• Fuller PM, Gooley JJ, Saper CB. Neurobiology of sleep-wake cycle, sleep architecture, circadian regulation and regulatory feed back. J Biol Rhythms 2006;21:482-93
   PubMed Web of Science ®Google Scholar
• Dijk DJ, Roth C, Landolt HP, Melatonin effect on daytime sleep in men: suppression of EEG low frequency activity and enhancement of spindle frequency activity. Neurosci Lett 1995;201:13-6
   PubMed Web of Science ®Google Scholar
• Jan JE, Reiter RJ, Wasdell MB, Bax M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res 2009;46:1-7
   PubMed Web of Science ®Google Scholar
• De Gennaro L, Ferrara M. Sleep spindles. An overview. Sleep Med Rev 2003;7:423-40
   PubMed Web of Science ®Google Scholar
• Jan JE, Wasdell MB, Reiter RJ, Melatonin therapy of pediatric sleep disorders: recent advances, why it works, who are the candidates and how to treat. Curr Pediatr Rev 2007;3:214-24
   Google Scholar
• Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003;15:432-7
   PubMed Web of Science ®Google Scholar
• Cajochen C, Münch M, Knoblauch V, Age-related changes in the circadian and homeostatic regulation of human sleep. Chronobiol Int 2006;23:461-4
   PubMed Web of Science ®Google Scholar
• Gorfine T, Zisapel N. Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt. Hum Brain Mapp 2009;30:541-52
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Trakht I, Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res 2009;165:201-14
   PubMed Web of Science ®Google Scholar
• Peled N, Shorer Z, Peled E, Pillar G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia 2001;42:1208-10
   PubMed Web of Science ®Google Scholar
• Willis GL. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci 2008;19:245-316
   PubMed Web of Science ®Google Scholar
• Willis GL. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug News Perspect 2005;18:437-44
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A. Advances on the development of subtype selective melatonin ligands. In: Pandi-Perumal SR, Cardinali DP, editors. Melatonin – from molecules to therapy. Nova Science Publishers, New York; 2007. p. 33-45
   Google Scholar
• Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci 2004;75:1843-56
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Mulchahey JJ, Scharf MB, The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005;66:384-90
   PubMed Web of Science ®Google Scholar
• 14th Annual drug delivery partnerships. BioSpace, 2008. Available from: http://www.biospace.com/news_story.aspx?NewsEntityId = 68002 [Last accessed 19 December 2009]
   Google Scholar
• Landolt H-P, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 2009;29:1795-809
   PubMed Web of Science ®Google Scholar
• Laudon M, Peleg-Shulman T. Novel pyrone-indole derivatives and process for their preparation. US20080027121A1; 2008
   Google Scholar
• Tan D-X, Reiter RJ, Manchester LC, Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med. Chem 2002;2:181-97
   Google Scholar
• Hardeland R, Tan D-X, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009;47:109-26
   PubMed Web of Science ®Google Scholar
• Hardeland R, Poeggeler B. Actions of melatonin, its structural and functional analogs in the central nervous system and the significance of metabolism. Cent Nerv Syst Agents Med Chem 2007;7:289-303
   Google Scholar
• Beresford IJM, Browning C, Starkey SJ, GR196429: a nonindolic agonist at high-affinity melatonin receptors. J Pharmacol Exp Ther 1998;285:1239-45
   PubMed Web of Science ®Google Scholar
• Rivara S, Mor M, Bedini A, Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem 2008;8:954-68
   PubMed Web of Science ®Google Scholar
• Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs 2009;10:691-701
   PubMed Web of Science ®Google Scholar
• Rivara S, Lodola A, Mor M, N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem 2007;50:6618-26
   PubMed Web of Science ®Google Scholar
• Rivara S, Vacondio F, Fioni A, N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. ChemMedChem 2009;4:1746-55
   PubMed Web of Science ®Google Scholar
• Catt JD, Johnson G, Keavy DJ, Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents. WO09825606; 1998
   Google Scholar
• Chen J, Dextraze P, Dodier M, Heterocyclic cis cyclopropane derivatives as melatonergic agents. US6214869; 2001
   Google Scholar
• Takaki KS, Sun L-Q, Johnson G, Benzoxazole derivatives as novel melatonergic agents. US6737431; 2004
   Google Scholar
• Rajaratnam SMW, Polymeropoulos MH, Fisher DM, Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373:482-91
   PubMed Web of Science ®Google Scholar
• Vachharajani NN, Yeleswaram K, Boulton DW. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci 2003;92:760-72
   PubMed Web of Science ®Google Scholar
• Birznieks G, Phadke D, Polymeropoulos MH. Treatment for depressive disorders. WO2007137247 A2; 2007
   Google Scholar
• Yin W, Hou H, Laudon M. NEU-P11, a novel melatonin agonist: effect on glucose transport in a cellular model of insulin resistance [abstract 0078]. Sleep 2008;31(Suppl):A26
   Google Scholar
• Laudon M, She M, Deng X, NEU-P11, a novel melatonin agonists inhibits weight gain and improves metabolic profiles in high-fat/high-sucrose-fed rats [abstract 0116]. Sleep 2009;32(Suppl):A39
   Google Scholar
• Laudon M, She M, Deng X, NEU-P11, a novel melatonin agonist improves insulin sensitivity in high-fat/high-sucrose-fed (HFSD) rats [abstract 0117]. Sleep 2009;32(Suppl):A39
   Google Scholar
• She M, Deng X, Guo Z, NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol Res 2009;59:248-53
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Smits M, Spence W, Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138-51
   PubMed Web of Science ®Google Scholar
• McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007;114:222-32
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Rough JN, Songer JB, The phase shift hypothesis for the circadian component of winter depression. Dialogues Clin Neurosci 2007;9:291-300
   PubMedGoogle Scholar
• Westrin A, Lam RW. Seasonal affective disorder: a clinical update. Ann Clin Psychiatry 2007;19:239-46
   PubMedGoogle Scholar
• Lewy AJ. Melatonin and human chronobiology. Cold Spring Harb Symp Quant Biol 2007;72:623-36
   PubMedGoogle Scholar
• Lamont EW, Legault-Coutu D, Cermakian N, Boivin DB. The role of circadian clock genes in mental disorders. Dialogues Clin Neurosci 2007;9:333-42
   PubMedGoogle Scholar
• Brunello N, Akiskal H, Boyer P, Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. J Affect Disord 1999;52:275-90
   PubMed Web of Science ®Google Scholar
• Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441-60
   PubMed Web of Science ®Google Scholar
• Caumo W, Levandovski R, Hidalgo MP. Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study. J Pain 2009;10:100-8
   Web of Science ®Google Scholar
• Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 2009;108:1146-51
   PubMed Web of Science ®Google Scholar
• Maldonado MD, Pérez-San-Gregorio MA, Reiter RJ. The role of melatonin in the immunoneuropsychology of mental disorders. Recent Pat CNS Drug Discov 2009;4:61-9
   PubMedGoogle Scholar
• Capuzzo M, Zanardi B, Schiffino E, Melatonin does not reduce anxiety more than placebo in the elderly undergoing surgery. Anesth Analg 2006;103:121-3
   PubMed Web of Science ®Google Scholar
• Chagraoui A, Protais P, Filloux T, Mocaë E. Agomelatine (S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology (Berl) 2003;170:17-22
   PubMed Web of Science ®Google Scholar
• Drijfhout WJ, de Vries JB, Homan EJ, Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol 1999;382:157-66
   PubMed Web of Science ®Google Scholar
• Browning C, Beresford I, Frazer N, Giles H. Pharmacological characterization of human recombinant mt1 and MT2 receptors. Br J Pharmacol 2000;129:877-86
   PubMed Web of Science ®Google Scholar
• Lew MJ, Flanders S. Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction. Br J Pharmacol 1999;126:1408-18
   PubMed Web of Science ®Google Scholar
• Jansen JM, Karlén A, Grol CJ, Hacksell U. Conformational properties of melatonin and two conformationally restricted agonists. A molecular mechanics and NMR spectroscopic study. Drug Des Discov 1993;10:115-33
   PubMedGoogle Scholar
• Sanchez RO, Karam F, Bambico FR, A novel melatonin partial agonist with sleep-promoting properties. ACNP 45th Annual Meeting, 3 – 7 December 2006; American College of Neuropsychopharmacology, Hollywood, FL; 2006. p. S157
   Google Scholar
• Sanchez RO, Cohen G, Spadoni G, Selective increase of slow wave sleep (SWS) by a novel melatonin partial agonist. 37th Annual Meeting Neuroscience 2007 (poster 244.4); 3 – 7 November, 2007; San Diego, CA G16, USA
   Google Scholar
• Karam F, Bambico FR, Sanchez RO, A novel melatonin partial agonist with sleep-promoting properties and anti-anxiety effects. 36th Annual Meeting Neuroscience 2006 (poster 830.21); 14 – 18 October 2006; Atlanta, GA, GG11 USA
   Google Scholar
• Nickelsen T, Samel A, Vejvoda M, Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int 2002;19:915-36
   PubMed Web of Science ®Google Scholar
• Rajaratnam SM, Polymeropoulos MH, Fischer DM, The melatonin agonist VEC-162 immediately phase-advances the human circadian system [abstract 0159]. Sleep 2006;29(Suppl):A54
   Google Scholar
• Birznieks G, Phadke D, Polymeropoulos MH. Melatonin agonist treatment WO2007137244; 2007
   Google Scholar
• Birznieks G, Scott C, Baroldi P, Melatonin agonist VEC-162 improves sleep onset and maintenance in a model of transient insomnia [abstract 0773]. Sleep 2007;30(Suppl):A264
   Google Scholar
• Feeney J, Birznieks G, Scott C, Melatonin agonist tasimelteon improves sleep in primary insomnia characterized by difficulty falling asleep [abstract 0127]. Sleep 2009;32(Suppl);A43
   Google Scholar
• Lavedan C, Polymeropoulos M, Birznieks G. Methods for the diagnosis and treatment of sleep disorders – Comprising the prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype. WO2009036257; 2009
   Google Scholar
• Mitkus S, Birznieks G, Thompson A, Lavedan C. Effect of a period 3 (PER3) gene polymorphism on response to tasimelteon treatment in a phase advance model of transient insomnia [abstract 0869]. Sleep 2009;32(Suppl):A284
   Google Scholar
• Laudon M, Urade Y, Huang Z. NEU-P11, a novel melatonin agonist: effects on sleep and EEG power spectra in rats [abstract 0106]. Sleep 2008;31(Suppl):A34-35
   PubMed Web of Science ®Google Scholar
• Tian S, Laudon M. NEU-P11, a novel GABA-enhancing melatonin agonist: antidepressant effects in the learned helplessness model in rats [abstract 0107]. Sleep 2008;31(Suppl):A35
   Google Scholar
• Cardinali D, Golombek D. Let there be sleep – on time. Lancet 2009;373:439-41
   PubMed Web of Science ®Google Scholar
• Potocki L, Glaze D, Tan D-X, Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet 2000;37:428-33
   PubMed Web of Science ®Google Scholar
• De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab 2006;17:291-8
   PubMed Web of Science ®Google Scholar
• De Leersnyder H, Claustrat B, Munnich A, Verloes A. Circadian rhythm disorder in a rare disease: Smith-Magenis syndrome. Mol Cell Endocrinol 2006;252:88-91
   PubMed Web of Science ®Google Scholar
• Carpizo R, Marténez A, Mediavilla D, Smith-Magenis syndrome: a case report of improved sleep after treatment with beta1-adrenergic antagonists and melatonin. J Pediatr 2006;149:409-11
   PubMed Web of Science ®Google Scholar
• Klerman EB. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Web appendix to online version of ref. 60, (2008) Available from: www.thelancet.com, doi: 10.1016/S0140-6736(08)61812-7
   Google Scholar